L3VLUP
ProSign in

MDXG in the 13F filings

Mimedx Group Inc · CUSIP 602496101

Sector · Medical devices and instrumentsTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Surgical, medical and electromedical devices
Quarter
Q2 2024Q1 2024Q4 2023Q1 2021Q4 2020Q4 2018Q3 2018Q2 2018Q1 2018Q4 2017Q3 2017Q2 2017
Quarter end
30 Sep 2017
the date the book describes
Filed
14 Nov 2017
latest of these filings; the earliest 14 Nov 2017
Managers listing it
2
at least, of 95 tracked, among listed positions
Comparable managers
83
filed both Q2 2017 and Q3 2017; 2 listed it in both
Shares listed
1,147,878
combined, among listed positions
Reported value
$14m
combined, at the quarter end

Managers listing MDXG in Q3 2017

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2017, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

2 of 2 holders

ActionFiling
PDT Partners LLC730,600$8.7m0.29%Added+223,13714 Nov 2017 (the filing on sec.gov)
Voloridge Investment Management LLC417,278$5.0m0.11%Added+316,40814 Nov 2017 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2017 to Q3 2017, among managers that listed it in both quarters or opened it.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
2 in Q2 2018 to 1 in Q2 2024

Tracked managers listing it, at least.

012342015201820212024
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
MDXG by quarter
QuarterHoldersReported valueBuyersSellers
Q4 20132$22mn.a.n.a.
Q2 20141$6.4mn.a.n.a.
Q3 20141$5.9mn.a.n.a.
Q4 20141$30mn.a.n.a.
Q1 20151$9.8mn.a.n.a.
Q2 20151$9.7mn.a.n.a.
Q3 20152$8.2mn.a.n.a.
Q4 20151$8.5mn.a.n.a.
Q2 20174$25mn.a.n.a.
Q3 20172$14mn.a.n.a.
Q4 20172$23mn.a.n.a.
Q1 20184$16mn.a.n.a.
Q2 20182$12mn.a.n.a.
Q3 20181$8.5mn.a.n.a.
Q4 20181$6.3mn.a.n.a.
Q4 20202$3.3mn.a.n.a.
Q1 20212$4.4mn.a.n.a.
Q4 20231$513k10
Q1 20242$2.0m20
Q2 20241$354k11

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

MDXG and LLY →MDXG and JNJ →MDXG and VRTX →Choose a stock to compare with MDXG →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own MDXG, latest filings →Back to the 13F Explorer →